|
|
|
|
|
Haya I. Aljohar, Abdulmajeed A. Alghamdi, Nasr Y. Khalil, Hany W. Darwish, Rashad Al-Salahi and Ibrahim A. Darwish
The Food and Drug Administration (FDA) has approved duvelisib (DUV) for managing follicular lymphoma, small lymphocytic lymphoma, and relapsed or refractory chronic lymphocytic leukemia. Seliciclib (SEL) is a candidate drug for these cancers, neurodegene...
ver más
|
|
|
|
|